v3.25.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Income Statement [Abstract]        
Net revenue $ 1,269,483 $ 2,397,652 $ 3,123,080 $ 4,804,043
Operating expenses:        
Direct costs and expenses 1,016,602 1,407,710 2,384,462 2,981,151
Research and development 311,372 402,433 678,758 796,072
Clinical development 129,279 51,462 267,632 100,422
Selling, general and administrative 2,214,561 2,472,775 4,667,110 4,658,719
Depreciation and amortization 113,229 151,070 267,817 300,707
Total operating expenses 3,785,043 4,485,450 8,265,779 8,837,071
Loss from operations (2,515,560) (2,087,798) (5,142,699) (4,033,028)
Other income (expense):        
Interest income 2,025 5,186 2,567 11,313
Interest expense (10,460) (22,249) (25,945) (45,799)
Other income 38,053 1 38,055 4,511
Other expense (483,043) (492,685)
Change in fair value of warrants issued (1,062,818) (1,062,818)
Total other income (expense), net (1,516,243) (17,062) (1,540,826) (29,975)
Net loss before provision for income tax expense (4,031,803) (2,104,860) (6,683,525) (4,063,003)
Income tax expense 28,984 5,419 37,679 9,091
Net loss $ (4,060,787) $ (2,110,279) $ (6,721,204) $ (4,072,094)
Net loss per common share, basic $ (0.17) $ (0.19) $ (0.20) $ (0.38)
Net loss per common share, diluted $ (0.17) $ (0.19) $ (0.20) $ (0.38)
Weighted average common shares outstanding, basic 24,021,546 11,389,308 20,148,211 10,655,483
Weighted average common shares outstanding, diluted 24,021,546 11,389,308 20,148,211 10,655,483

Source